Application of clopidogrel in preparation of medicine for preventing renal ischemia reperfusion injury

By using clopidogrel as a ferrodysfunction inhibitor, ferrodysfunction was inhibited through the FSP1 pathway, and the prevention problem of renal ischemia and reperfusion injury was solved, and effective protection of renal IRI was achieved.

CN119745876APending Publication Date: 2025-04-04THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV
2 Cites 0 Cited by

Patent Information

Application Number
CN202411991822.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-31
Publication Date
2025-04-04

AI Technical Summary

Technical Problem

There is no effective measure to prevent renal ischemia and reperfusion injury (IRI) in the prior art. Iron death plays an important role in the pathological mechanism of renal IRI, and there is a lack of therapeutic strategies targeting the iron death pathway.

Method used

Clopidogrel is used as a ferrodystrophy inhibitor to inhibit ferrodystrophy through the FSP1 pathway, thereby preventing renal ischemia and reperfusion injury.

Benefits of technology

clopidogrel can significantly prevent renal IRI in mice by administering 2 hours in advance, inhibit cell ferrodysfunction induced by multiple ferrodysfunction inducers, reduce lipid peroxidation and increase in intracellular Fe2+ content, and have significant renal protection effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to an application of clopidogrel in preparation of a medicine for preventing renal ischemia-reperfusion injury. The medicine is administrated 2 hours ahead of time, so that mouse kidney IRI can be prevented, and cell ferroptosis is inhibited through an FSP1 way. In-vitro cell experiments show that in various cell lines such as HT1080, HK2 and the like, clopidogrel can inhibit ferroptosis induced by ferroptosis inducers (such as RSL3, IKE, FIN56 or JKE-1674), and cell lipid peroxidation and intracellular Fe < 2 + > content increase caused by ferroptosis can be partially recovered. The clopidogrel disclosed by the invention has an obvious effect of inhibiting cell ferroptosis and is beneficial to prevention of renal ischemia reperfusion injury.
Need to check novelty before this filing date? Find Prior Art